Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Hamilton Health Sciences Nephrology Divisional Research Funds, St. Joseph's Healthcare |
---|---|
Information provided by: | McMaster University |
ClinicalTrials.gov Identifier: | NCT00182156 |
This study is examining the effects of short daily hemodialysis on platelet function, fluid volume control, arterial stiffness and patient quality of life, as compared to conventional hemodialysis.
Condition |
---|
End-Stage Renal Disease Thrombocytopathy Cardiovascular Diseases |
Study Type: | Observational |
Study Design: | Cohort, Cross-Sectional |
Official Title: | Cohort Study Examining the Effects of Short Daily Hemodialysis As Compared to Conventional Hemodialysis in Outpatients Treated at St Joseph's Healthcare, Hamilton |
Estimated Enrollment: | 40 |
Study Start Date: | October 2004 |
Estimated Study Completion Date: | December 2008 |
Estimated Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
Groups/Cohorts |
---|
1
conventional HD
|
2
short daily HD
|
3
PD
|
Bleeding is a common cause of morbidity and mortality in patients with end stage renal disease. A major cause of uremic bleeding is due to platelet dysfunction. It has been theorized that in renal failure, toxins accumulate, some of which inhibit primary hemostasis. All aspects of normal platelet function are affected. Platelet function has previously been difficult to quantify but recently a novel test, the platelet function analyzer (PFA-100) has been determined to be both sensitive and specific in assessing platelet function. Conventional hemodialysis (CHD) has been shown to partially correct thrombocytopathy. Enhanced uremic clearance can now be attained through the use of short daily hemodialysis (SDHD). Cardiovascular disease is the most common cause of mortality in dialysis patients, accounting for 40% of deaths. Volume overload is associated with high blood pressure, left ventricular hypertrophy and elevated markers of inflammation and these factors have been associated with increased cardiovascular mortality. SDHD has been shown to control blood pressure and limit volume expansion. Pulse wave velocity (PWV) has been used to assess arterial compliance and reduction of arterial elasticity of large and small arteries which have been associated with cardiovascular outcomes.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Short daily HD v PD v conventional HD
Inclusion Criteria:
Exclusion Criteria:
Canada, Ontario | |
St. Joseph's Healthcare | |
Hamilton, Ontario, Canada, L8N 4A6 |
Principal Investigator: | Azim Gangji, MD | Clinical Scholar, Medicine |
Principal Investigator: | Catherine M Clase, MD | Associate Professor, Medicine |
Responsible Party: | McMaster University ( Dr Azim Gangji ) |
Study ID Numbers: | Nephrology Divisional Funds |
Study First Received: | September 10, 2005 |
Last Updated: | June 16, 2008 |
ClinicalTrials.gov Identifier: | NCT00182156 History of Changes |
Health Authority: | Canada: Health Canada |
hemodialysis platelet function analyzer bioimpedance pulse wave velocity end stage renal disease |
Thrombocytopathy Renal Insufficiency Urologic Diseases Renal Insufficiency, Chronic Hematologic Diseases |
Blood Platelet Disorders Kidney Failure, Chronic Kidney Diseases Kidney Failure |
Renal Insufficiency Urologic Diseases Renal Insufficiency, Chronic Hematologic Diseases Blood Platelet Disorders |
Kidney Failure, Chronic Cardiovascular Diseases Kidney Diseases Kidney Failure |